CAN FITE BIOPHARMA LTD-ADR (CANF)
US13471N3008 - ADR
2.24 -0.09 (-3.86%)
Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023
Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time for another dive into the biggest pre-market stock movers as we see what's moving the market on Thursday morning!
PXD, TGTX and EH among pre-market gainers
OncoSec Medical (ONCS) +65%. GlucoTrack (GCTK) +29%
Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment
Can-Fite Reports 2022 Financial Results & Provides Clinical Update
Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting
Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed
Can-Fite BioPharma announces $7.5M direct offering (NYSE:CANF)
Can-Fite BioPharma (CANF) has entered agreements for the purchase and sale of 1M ADSs at a purchase price of $5.50 per ADS, in a registered direct offering
Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement
Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow
Can-Fite announces ADS ratio change (NYSE:CANF)
Can-Fite BioPharma (CANF) said it will change the ratio of its American Depositary Shares to ordinary shares from one ADS representing 30 ordinary shares to a new ratio of one...
Can-Fite Announces ADS Ratio Change
CANF stock gains on study data for liver cancer therapy (NYSE:CANF)
Can-Fite BioPharma (CANF) gained pre-market Wednesday on latest findings on its liver cancer therapy Namodenoson ahead of two investor events. Read the full story here.
Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer
Multiple Shots On Goal: Can-Fite’s Late-Stage Clinical Pipeline Hits Positive Results
Multiple countries are approving Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) ’s Namodenoson for compassionate use in patients with advanced liver cancer.
Can-Fite’s Partner Vetbiolix is Heading into a European Multicentric Clinical Trial with Piclidenoson for the Treatment of Pets’ Osteoarthritis
Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update
Can-Fite: Positive New Data from it’s Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up.
Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting®
